BioStabilization Systems (BoSS)
ARPA-H's BoSS program funds research to develop room-temperature storage technologies for cell-based biologic medicines, aiming to eliminate ultra-cold storage and improve global access to advanced therapies.
Funder: Advanced Research Projects Agency for Health
Due Dates: February 19, 2026 (Solution Summary for Technical Performers) | March 26, 2026 (Solution Pitch for Technical Performers) | April 17, 2026 (Solution Summary for IV&V Partners) | May 15, 2026 (Solution Pitch for IV&V Partners)
Funding Amounts: Funding level not explicitly stated; multi-phase projects with milestone-based payments; program emphasizes aggressive, outcome-based funding agreements.
Summary: Supports development of room-temperature preservation technologies for biologic medicines to eliminate the need for ultra-cold storage and improve global access.
Key Information: Submission of a Solution Summary is required to remain eligible; teaming with diverse partners is encouraged; program uses Other Transactions, not standard grants.
Description
The BioStabilization Systems (BoSS) program, funded by the Advanced Research Projects Agency for Health (ARPA-H), seeks to revolutionize the storage and distribution of advanced biologic medicines by developing technologies that enable long-term, room-temperature preservation of cell-based therapies and biologics. The program aims to eliminate the need for ultra-cold refrigeration, inspired by natural mechanisms found in extremophile organisms and advances in materials science. By making biologics as easy to store and ship as conventional drugs, BoSS targets reduced costs, minimized risk of product loss, and expanded access to life-saving treatments, particularly in remote or resource-limited settings. The program is structured in multiple phases and emphasizes milestone-driven progress, aggressive technical goals, and the expectation of commercial viability and adoption.
